Where does Aleva Neurotherapeutics rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Aleva Neurotherapeutics ranks #15,804 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Aleva Neurotherapeutics hold?

Aleva Neurotherapeutics holds 18 US utility patents granted between 2016 and 2023, spanning 4 technology areas.

What is Aleva Neurotherapeutics's Innovation Score?

Aleva Neurotherapeutics has an Innovation Score of 34.7 out of 100 (48th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Aleva Neurotherapeutics focus on?

Aleva Neurotherapeutics's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 17 patents, ranking #211 of 1,943 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Aleva Neurotherapeutics's patent grant rate increasing or decreasing?

Aleva Neurotherapeutics's recent grant velocity is +0% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Aleva Neurotherapeutics's patents?

Aleva Neurotherapeutics's patents average 19.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Aleva Neurotherapeutics patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Aleva Neurotherapeutics

USPTO PatentsView assignee record - 18 granted patents across 4 technology areas, recorded in grant years 2016–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Aleva ranks #15,804 of 49,997 tracked US assignees by granted-patent volume, with 18 patents across 4 technology areas.

#15,804
of 49,997 US assignees by volume: 48th percentile
by Innovation Score (34.7/100): 19.8
avg claims per patent: +0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R15804 · Foreign Corporation #15,804 · 18 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

GRANTS-MICRO 18 grants
MID-PACK #15,804/49,997
PHOTO-FINISH Adaptam
CPC-NARROW A61N · 4 areas
INNOV-THIN 34.7/100
CLAIMS-RICH 19.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-FLAT +0% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Adaptam Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Aleva’s 34.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.2 pts (29%) Velocity 5.6 pts (16%) Breadth 7.1 pts (20%) Claim depth 11.9 pts (34%)

Qualcomm Incorporated · highest

85
Aleva Neurotherapeut… · this assignee

35
3D Lighting… · lowest

7

What this shows Aleva's Innovation Score is 34.7/100 (48th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Aleva?

Each dot is one of Aleva’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Aleva’s own 19.8 claims/patent is ABOVE the 18.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Aleva vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Aleva's grants concentrate

Aleva Neurotherapeutics is a focused PatentsView assignee: 4 CPC subclasses with 94.4% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2018 (4 grants) versus a trough of 1 in 2017. By volume, Aleva sits between Adaptam Inc. and AlpineReplay, Inc..

Aleva's three-year grant acceleration

Aleva Neurotherapeutics shows 5 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Adaptam

18
Advanced Custom E…

18
Aira

18
Albert Gad

18
Alfresco Software

18
All Space Networks

18
Allstar Marketing…

18
Alpinereplay

18
Aleva Neurotherap… ◀

18

What this shows Aleva holds 18 patents at rank #15,819, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Aleva

By rank, the assignees closest to #15,819 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Aleva's primary technology class.

Aleva's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 48th percentile higher than 48% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Aleva Neurotherapeutics patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	11.1%
2017	1	5.6%
2018	4	22.2%
2019	2	11.1%
2020	1	5.6%
2021	3	16.7%
2022	3	16.7%
2023	2	11.1%

Which technologies does Aleva Neurotherapeutics patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 17

A61B - DIAGNOSIS; SURGERY; Identification 14

H05K - Printed CIRCUITS; Casings OR Constructional Details OF Electric APPARATUS; Manufacture OF Assemblages OF Electrical Components 7

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 1

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Aleva Neurotherapeutics's patent record in context - here's where to go next.

Aleva Neurotherapeutics's lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 94.4% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #15,804 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Aleva Neurotherapeutics against Adaptam Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.